Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanine nucleotide-binding protein G(i) subunit alpha-3 (GNAI3) is the inhibitory alpha subunit of heterotrimeric G proteins, which mediate intracellular signaling downstream of G protein-coupled receptors (GPCRs). GNAI3’s primary function is to inhibit adenylyl cyclase, decreasing cyclic AMP (cAMP) levels and influencing various pathways including cell division, ion channel regulation, and vesicle trafficking. Mutations in GNAI3 disrupt craniofacial development, causing auriculocondylar syndrome. Although drugs do not directly target GNAI3 in clinical practice, it remains critical in pharmacological pathways and is a key node in the molecular signaling network of many therapeutic agents and biological processes.
Most drugs act indirectly: Inhibition of G protein coupled receptor (GPCR) activity, leading to modulation of GNAI3-regulated signaling cascades. Inhibition of adenylyl cyclase, resulting in reduced intracellular cAMP. Activation or inhibition of ion channels through GPCR-dependent GNAI3 pathways.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanine nucleotide-binding protein G(i) subunit alpha-3 (GNAI3).